A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1 Completed 25 enrolled Pfizer

RandomizedCrossoverOpen-labelOther

Summary

This is a Phase 1, randomized, 2-way crossover, multiple dose, open label study of the effect of PF-04965842 on midazolam PK in healthy subjects. The study will demonstrate the effect of multiple dose PF-04965842 on the pharmacokinetics of a single, oral dose of midazolam in healthy subjects.

Timeline

Start: 2018-07-03
Primary completion: 2018-10-16
Completion: 2018-10-16

Publications

Wang X, Dowty ME, Tripathy S, Le VH, Huh Y, Curto M, Winton JA, O'Gorman MT, Chan G, Malhotra BK. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. Eur J Drug Metab Pharmacokinet. 2024 May;49(3):367-381. doi: 10.1007/s13318-024-00893-5. Epub 2024 Mar 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abrocitinib	Small molecule	200 mg	Oral
Subject	Midazolam	Small molecule	2 mg	Oral

Indications

No indication recorded.